Welp today I learned that in July, the black interior of the vehicle I drive gets hotter than the melting point of naproxen capsules.

#mess #melted #dosage #impossible #to #determine

3 Ways to Determine Benadryl Dosage for Dogs #howto #diy #Dosage

Melatonin in sleep-aid gummies can be off by up to 350%, study finds | Ars Technica https://arstechnica.com/science/2023/04/crazy-variability-of-melatonin-in-sleep-aid-gummies-may-keep-you-up-at-night #santé_publique #sommeil #mélatonine #dosage #médicament #à_traduire #1st_revue #0_archivebox #2nd_frm

Hier so ein paar Beispiele für ärztliche Verordnungen: 😅

---
RT @Adrian0023x
#alprazolam #xanax
#Xanax #drugs #alprazolam #nofenty #percs #m30 #adderall #ritalin #dosage #2mg #usps #Bitcoin #ETH #deliveryguy #dallasplug #TX #FL #ChicagoMed #props #drugree #ghsp #drugtwt #pfizer #alprazolam #xanax #molly #nyc #NewYorkCity #Nycplug #smokepurp #wocklean
https://twitter.com/Adrian0023x/status/1646666178184589312

Complicate this 🌍 you 🎁 for me
I'm acquainted with your suffering
Hold me up to all whom you've deceived
Promises you break you still believe
And all your weight
It falls on me
It brings me down
And all your weight
It falls on me
It falls on me
#Heavy
#EdRoland
#CollectiveSoul
#Dosage 9 Feb 1999
🐝🐝👄🐝🐝
#progressive #rock #pop #1990s
#movies #1970s
https://youtu.be/spY8vWqNKF8

@megmaker Many Brut Zeros are exactly that, but I remember this as a stand out in the Tarlant line-up at Temps des Copains, Nantes. #wine #Champagne #dosage

Ever since the Human #Genome Project got rolling about thirty years ago (!) there’s been a lot of hope, and a lot of hype, about “#personalized #medicine” or “#precision medicine.” When it became clear that as always, the results weren’t going to match the hype, a lot of the hope went away too. This is a mistake.

I’d like to talk about a quiet revolution in precision medicine: #genetic #dosage guidelines, a.k.a. #pharmacogenomic #labeling. The basic idea is that if you carry certain genetic #variants, you may need considerably more or less of a particular medication than the standard dose. Back in the ’90s, the kind of genetic #analysis needed to make use of that information was far too expensive and time-consuming for #clinical practice. These days you can get a complete #sequence in a matter of hours, for the same cost as a battery of standard blood tests.

Fifteen years ago or so, the FDA approved the first pharmacogenomic labeling, for #warfarin. I was lucky enough to be in the room when the researchers made the announcement, and you could have heard a pin drop. Now it’s routine, and there’s a very long list: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Everyone reacts to #medications differently. For most patients, most medications, and most diseases, there’s a fairly broad range of clinical effectiveness between “too little to do any good” and “way too much.” But for a substantial number of all of the above, the range is much narrower—and when you add up all the special cases, you get a hell of a lot of people!

A lot of #drugs never get approved, despite showing promise in clinical #trials, because they only help a portion of the study population. Regulatory bodies like the #FDA are notoriously resistant to #subgroup analysis, and I get why: it’s very easy to cherry-pick those subjects in a clinical trial who happen to do well, and then come up with a post hoc explanation for why the test treatment worked for them but not for other participants. Some bad drugs have made it to market because of this kind of chicanery. But of course sometimes there’s a real reason one group does better, and as long as genetic testing is part of the study design from the start, it’s becoming possible to convince regulators that reason is valid.

My work is mostly upstream of this, in the drug #target #discovery phase: finding disease-related #genes and #proteins that might be modifiable with the right medication. Since it’s part of the project from the start, that makes trial design easier, and the results more likely to be accepted. But I’d really like to see more #genomic analysis on drugs that aren’t designed that way too, and I think we’re getting there.

Genetic dosage guidelines, though, are making a real difference in current practice. There are still considerable debates over the merits of many labelings, driven partly by legitimate #statistical concerns and partly by ideology. But the principle is proven beyond reasonable doubt, and it’s saving lives and relieving suffering right now, every day. Much more to come.

Ever since the Human #Genome Project got rolling about thirty years ago (!) there’s been a lot of hope, and a lot of hype, about “#personalized #medicine” or “#precision medicine.” When it became clear that as always, the results weren’t going to match the hype, a lot of the hope went away too. This is a mistake.

I’d like to talk about a quiet revolution in precision medicine: #genetic #dosage guidelines, a.k.a. #pharmacogenomic #labeling. The basic idea is that if you carry certain genetic #variants, you may need considerably more or less of a particular medication than the standard dose. Back in the ’90s, the kind of genetic #analysis needed to make use of that information was far too expensive and time-consuming for #clinical practice. These days you can get a complete #sequence in a matter of hours, for the same cost as a battery of standard blood tests.

Fifteen years ago or so, the FDA approved the first pharmacogenomic labeling, for #warfarin. I was lucky enough to be in the room when the researchers made the announcement, and you could have heard a pin drop. Now it’s routine, and there’s a very long list: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Everyone reacts to #medications differently. For most patients, most medications, and most diseases, there’s a fairly broad range of clinical effectiveness between “too little to do any good” and “way too much.” But for a substantial number of all of the above, the range is much narrower—and when you add up all the special cases, you get a hell of a lot of people!

A lot of #drugs never get approved, despite showing promise in clinical #trials, because they only help a portion of the study population. Regulatory bodies like the #FDA are notoriously resistant to #subgroup analysis, and I get why: it’s very easy to cherry-pick those subjects in a clinical trial who happen to do well, and then come up with a post hoc explanation for why the test treatment worked for them but not for other participants. Some bad drugs have made it to market because of this kind of chicanery. But of course sometimes there’s a real reason one group does better, and as long as genetic testing is part of the study design from the start, it’s becoming possible to convince regulators that reason is valid.

Much of my work is upstream of this, in the drug #target #discovery phase: finding disease-related #genes and #proteins that might be modifiable with the right medication. Since it’s part of the project from the start, that makes trial design easier, and the results more likely to be accepted. But I’d really like to see more #genomic analysis on drugs that aren’t designed that way too, and I think we’re getting there.

Genetic dosage guidelines, though, are making a real difference in current practice. There are still considerable debates over the merits of many labelings, driven partly by legitimate #statistical concerns and partly by ideology. But the principle is proven beyond reasonable doubt, and it’s saving lives and relieving suffering right now, every day. Much more to come.

Ever since the Human #Genome Project got rolling about thirty years ago (!) there’s been a lot of hope, and a lot of hype, about “personalized medicine” or “precision medicine.” When it became clear that as always, the results weren’t going to match the hype, a lot of the hope went away too. This is a mistake.

I’d like to talk about a quiet revolution in precision medicine: #genetic #dosage guidelines, a.k.a. #pharmacogenomic #labeling. The basic idea is that if you carry certain genetic #variants, you may need considerably more or less of a particular medication than the standard dose. Back in the ’90s, the kind of genetic #analysis needed to make use of that information was far too expensive and time-consuming for #clinical practice. These days you can get a complete #sequence in a matter of hours, for the same cost as a battery of standard blood tests.

Fifteen years ago or so, the FDA approved the first pharmacogenomic labeling, for #warfarin. I was lucky enough to be in the room when the researchers made the announcement, and you could have heard a pin drop. Now it’s routine, and there’s a very long list: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Everyone reacts to #medications differently. For most patients, most medications, and most diseases, there’s a fairly broad range of clinical effectiveness between “too little to do any good” and “way too much.” But for a substantial number of all of the above, the range is much narrower—and when you add up all the special cases, you get a hell of a lot of people!

A lot of #drugs never get approved, despite showing promise in clinical #trials, because they only help a portion of the study population. Regulatory bodies like the #FDA are notoriously resistant to #subgroup analysis, and I get why: it’s very easy to cherry-pick those subjects in a clinical trial who happen to do well, and then come up with a post hoc explanation for why the test treatment worked for them but not for other participants. Some bad drugs have made it to market because of this kind of chicanery. But of course sometimes there’s a real reason one group does better, and as long as genetic testing is part of the study design from the start, it’s becoming possible to convince regulators that reason is valid.

Much of my work is upstream of this, in the drug #target #discovery phase: finding disease-related #genes and #proteins that might be modifiable with the right medication. Since it’s part of the project from the start, that makes trial design easier, and the results more likely to be accepted. But I’d really like to see more #genomic analysis on drugs that aren’t designed that way too, and I think we’re getting there.

Genetic dosage guidelines, though, are making a real difference in current practice. There are still considerable debates over the merits of many labelings, driven partly by legitimate #statistical concerns and partly by ideology. But the principle is proven beyond reasonable doubt, and it’s saving lives and relieving suffering right now, every day. Much more to come.

#cannabis #dosage #thc #oil

Dosimetry: Measuring Radiation - Thanks to stints as an X-ray technician in my early 20s followed by work in variou... - https://hackaday.com/2022/11/07/dosimetry-measuring-radiation/ #measurement #radiation #featured #interest #science #dosage

Dosimetry: Measuring Radiation

https://hackaday.com/2022/11/07/dosimetry-measuring-radiation/

#measurement #radiation #Featured #Interest #Science #dosage

#International_Tech_News | #BIG_GOV | #CLIMATE_CHANGE | #BIG_EMISSIONS

#Birth_control in #DOGS I HOW to #ABORT a DOG #PREGNANCY at HOME I Dog #Abortion_Pills I Depo shots dogs

This lecture explains the novel therapies for #birth_control in dogs by explaining the #dosage, #side_effects, and mode of administration of the newer drugs that include ..

https://youtu.be/KjHRMoj3PWM

Disclaimer: http://DavidVTV.com and/or its owners [http://Tastingtraffic.com] ..

#20minutes #santé "Arrêter les règles : Comment et pourquoi on a fabriqué de fausses menstruations" #pilule #règles #menstruation #hormones #dosage ... https://www.20minutes.fr/sante/2728863-20200602-arreter-regles-comment-pourquoi-fabrique-fausses-menstruations

#20minutes #santé "Arrêter les règles : Comment et pourquoi on a fabriqué de fausses menstruations" #pilule #règles #menstruation #hormones #dosage ... https://www.20minutes.fr/sante/2728863-20200602-arreter-regles-comment-pourquoi-fabrique-fausses-menstruations